Evidence map›Paper›PMID 33462050›Full record

ArticleBMJ case reports2021

Amlan Kusum Datta, Partha Debnath, Uddalak Chakraborty, Atanu Chandra

Open access · greenAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ case reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Amlan Kusum DattaNeurology, Institute of Postgraduate Medical Education and Research Bangur Institute of Neurology, Kolkata, India.
Partha DebnathGastroenterology, Topiwala National Medical College, Mumbai, India.ORCID http://orcid.org/0000-0001-6367-545X
Uddalak ChakrabortyInternal Medicine, RG Kar Medical College and Hospital, Kolkata, India.
Atanu ChandraInternal Medicine, RG Kar Medical College and Hospital, Kolkata, India chandraatanu123@gmail.com.ORCID http://orcid.org/0000-0002-3809-8926
R. G. Kar Medical College and Hospital · INBangur Institute of Neurosciences · INTopiwala National Medical College & BYL Nair Charitable Hospital · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dasatinib, an oral tyrosine kinase inhibitor, is approved for therapy of chronic myeloid leukaemia (CML). Common adverse effects of this therapy include myelosuppression, fluid retention and diarrhoea. However,

Indexed as

AdultAntineoplastic AgentsClostridioides difficileClostridium InfectionsDasatinibDiarrheaHumansLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMaleAntineoplastic AgentsDasatinibChronic Myeloid LeukemiaDasatinibInfection (gastroenterology)Unwanted effects / adverse reactions

Identifiers

PMID33462050
PMCPMC7813327
OpenAlexW3125073716

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.